Recombinant outer membrane protein Q and putative lipoprotein from <i>Bordetella pertussis</i> inducing strong humoral response were not protective alone in the murine lung colonization model
Despite high vaccination coverage after introduction of whole cell (wP) and acellular pertussis (aP) vaccines, pertussis
resurgence has been reported in many countries. aP vaccines are commonly preferred due to side effects of wP vaccines and formulated
with aluminum hydroxide (Alum), which is not an effective adjuvant to eliminate Bordetella pertussis. Low efficiency of current aP
vaccines is thought to be the main reason for the resurgence for which newer generation aP vaccines are needed. In the present study,
immunogenicity and protective efficacy of outer membrane protein Q (OmpQ) and a putative lipoprotein (Lpp) from
B. pertussis were
investigated in mice by using two different adjuvants, monophosphoryl lipid A (MPLA) or Alum. OmpQ and putative Lpp were cloned,
expressed, and purified from
Escherichia coli.
The proteins were formulated to immunize mice. Both recombinant OmpQ and putative
Lpp induced a significant increase in immunoglobulin G1 (IgG1) and immunoglobulin G2a (IgG2a) responses compared to the control
group. Moreover, MPLA-adjuvanted formulations resulted in higher IgG2a levels than Alum-adjuvanted ones. However, there were
no significant differences between test and control groups regarding interferon-gamma (IFN-γ) levels, and the mice lung colonization
experiments indicated that neither rOmpQ nor rLpp could confer protection alone against
B
.
pertussis
challenge.
___
- Allen AC, Mills KHG (2014). Improved pertussis vaccines based
on adjuvant that induce cell-mediated immunity. Expert Rev
Vaccines 13: 1253-1264.
- Altındiş E, Tefon BE, Yıldırım V, Özcengiz E, Becher D, Hecker M,
Özcengiz G (2009). Immunoproteomic analysis of
Bordetella
pertussis
and identification of new immunogenic proteins.
Vaccine 27: 542-548.
- Barnard A, Mahon BP, Watkins J, Redhead K, Mills KHG (1996).
Th1/Th2 cell dichotomy in acquired immunity to
Bordetella
pertussis
: variables in the in vivo priming and in vitro cytokine
detection techniques affect the classification of T-cell subsets as
Th1, Th2 or Th0. Immunology 87: 372-380.
- Burns DL, Meade BD, Messionnier NE (2014). Pertussis resurgence:
perspectives from the working group meeting on pertussis on
the causes, possible paths forward, and gaps in our knowledge.
J Infect Dis 209: S32-S35.
- CDC (2014). Pertussis epidemic - California, 2014. MMWR-Morbid
Mortal W 63: 1129-1132.
- Chiappini E, Stival A, Galli L, de Martino M (2015). Pertussis re-
emergence in the post-vaccination era. BMC Infect Dis 13: 151.
- de Gouw D, O’Serra D, de Jonge MI, Hermans PWM, Wessels HJCT,
Zomer A, Yantorno OM, Diavatopoulos DA, Mooi FR (2014).
The vaccine potential of
Bordetella
pertussis
biofilm-derived
membrane proteins. Emerg Microbes Infec 3: e58.
- Edwards KM (2014). Review of the laboratory approaches to the
detection of antibody and cell-mediated immunity to pertussis
disease and vaccine. Expert Rev Vaccines 13: 1183-1190.
- Edwards KM, Berbers GA (2014). Immune responses to pertussis
vaccines and disease. J Infect Dis 209: S10-S15.
- Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB,
Steinhoff MC, Anderson EL, Englund JA, Pichichero ME,
Deloria MA (1995). Comparison of 13 acellular pertussis
vaccines: overview and serologic responses. Pediatrics 96: 548-
557.
- Fedel G, Cassone A, Ausiello CM (2015). T-cell immune responses
to
Bordetella
pertussis
infection and vaccination. Pathog Dis 73:
ftv051.
- Feng S, Barthold SW, Telford SR, Fikrig E (1996). P55, an
immunogenic but nonprotective 55-Kilodalton
Borrelia
burgdorferi
protein in murine Lyme disease. Infect Immun 64:
363-365.
- Finger H, von Koenig CHW (1996).
Bordetella
. In: Baron S, editor.
Medical Microbiology. 4th ed. Galveston, TX, USA: University
of Texas Medical Branch at Galveston.
Finkelman FD, Katona IM, Mosmann TR, Coffman RL (1988).
IFN-gamma regulates the isotype of Ig secreted during in vivo
humoral immune responses. J Immunol 140:
1022-1027.
- Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M,
Ooi P, Smith RP, Weise P, Wetherell M et al (2004). Vaccine
potential of the
Neisseria
meningiditis
2086 lipoprotein. Infect
Immun 72: 2088-2100.
- Gigliotti F, Wiley JA, Harmsen AG (1998). Immunization with
Pneumocystis
carinii
gpA is immunogenic but not protective
in a mouse model of
P
. c
arinii
pneumonia. Infect Immun 66:
3179-3182.
- Guan Q, Wang X, Wang X, Teng D, Mao R, Zhang Y, Wang J (2015).
Recombinant outer membrane protein A induces a protective
immune response against
Escherichia
coli
infection in mice.
Appl Microbiol Biotechnol 99:
5451-5460.
- Hayes JA, Erben E, Lamberti Y, Ayala M, Maschi F, Carbone C, Gatti
B, Parisi G, Rodriguez ME (2011). Identification of a new
protective antigen of
Bordetella
pertussis
. Vaccine 29: 8731-
8739.
- Hayes JA, Erben E, Lamberti Y, Principi G, Maschi F, Ayala M,
Rodrigues ME (2013).
Bordetella
pertussis
iron regulated
proteins as potential vaccine components. Vaccine 31: 3543-
3548.
- Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP,
Stibitz ES (2014). Pertussis pathogenesis – what we know and
what we don’t know. J Infect Dis 209: 982-985.
Higgs R, Higgins SC, Ross PJ, Mills KGH (2012). Immunity to the
respiratory pathogen
Bordetella
pertussis
. Mucosal Immunol 5:
485-500.
- Hinode D, Nakamura R, Grenier D, Mayrand D (1998). Cross-
reactivity of specific antibodies directed to heat shock proteins
from periodontopathogenic bacteria and of human origin.
Oral Microbiol Immunol 13: 55-58.
- King AJ, Berbers G, van Oirschot HFLM, Hoogerhout P, Knipping
K, Mooi FR (2001). Role of the polymorphic region 1 of
the
Bordetella
pertussis
protein pertactin in immunity.
Microbiology 147: 2885-2895.
- Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, Lan R
(2012). Selection and emergence of pertussis toxin promoter
ptxP3 allele in the evolution of
Bordetella
pertussis
. Infect
Genet Evol 12: 492-495.
- Maleki F, Khosravi A, Nasser A, Taghinejad H, Azizian M (2016).
Bacterial heat shock protein activity. J Clin Diagn Res 10:
BE01-BE03.
- Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer
KD, Gilleland HE, Staczek J, Domdey H, von Specht BU
(1999). Safety and immunogenicity of a
Pseudomonas
aeruginosa
hybrid outer membrane protein F-I vaccine in
human volunteers. Infect Immun 67:
1461-1470.
- Marr N, Oliver DC, Laurent V, Poolman J, Denoel P, Fernandez
RC (2008). Protective activity of the
Bordetella
pertussis
BrkA
autotransporter in the murine lung colonization model.
Vaccine 26: 4306-4311.
- McKee AS, Munks MW, Marrack P (2007). How do adjuvants
work? Important considerations for new generation adjuvants.
Immunity 27: 687-690.
- Mooi FR, He Q, Guiso N (2007). Phylogeny, evolution, and
epidemiology of
Bordetellae
. In: Locht C, editor.
Bordetella
:
Molecular Microbiology. Norfolk, UK: Horizon Bioscience,
pp. 17-45.
- Mooi FR, van Loo IHM, van Gent M, He Q, Bart MJ, Heuvelman
KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N
et al. (2009).
Bordetella
pertussis
strains with increased toxin
production associated with pertussis resurgence. Emerg Infect
Dis 15: 1206-1213.
- Mooi FR, van Oirschot HFLM, Heuvelman K, van der Heide HGJ,
Gaastra W, Willems JL (1998). Polymorphism in the
Bordetella
pertussis
virulence factors P.69/pertactin and pertussis toxin
in the Netherlands: temporal trends and evidence for vaccine-
driven evolution. Infect Immun 66: 670-675.
- Okay S, Özcengiz E, Gürsel İ, Özcengiz G (2012). Immunogenicity
and protective efficacy of the recombinant
Pasteurella
lipoprotein E and outer membrane protein H from
Pasteurella
multocida
A:3 in mice. Res Vet Sci 93:
1261-1265.
- Ramagli LS, Rodriguez LV (1985). Quantitation of microgram
amounts of protein in two-dimensional polyacrylamide gel
electrophoresis sample buffer.
Electrophoresis 6: 559-563.
- Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle
EC, McLoughlin RM, Mills KH (2013). Relative contribution
of Th1 and Th17 cells in adaptive immunity to
Bordetella
pertussis
: towards the rational design of an improved acellular
pertussis vaccine. PLoS Pathog 9:
e1003264.
- Ryder AB, Tollefson SJ, Podsiad AB, Johnson JE, Williams JV (2010).
Soluble recombinant human metapneumovirus G protein is
immunogenic but not protective. Vaccine 28:
4145-4152.
- Sealey KL, Harris SR, Fry NK, Hurst LD, Gorringe AR, Parkhill J,
Preston A (2015). Genomic analysis of isolates from the United
Kingdom 2012 pertussis outbreak reveals that vaccine antigen
genes are unusually fast evolving. J Infect Dis 212:
294-301.
- Sealey KL, Belcher T, Preston A (2016).
Bordetella
pertussis
epidemiology and evolution in the light of pertussis resurgence.
Infect Genet Evol 40: 136-143.
- Tefon BE, Maaß S, Özcengiz E, Becher D, Hecker M, Özcengiz G
(2011). A comprehensive analysis of
Bordetella
pertussis
surface
proteome and identification of new immunogenic proteins.
Vaccine 29:
3583-3595.
- Tefon BE, Özcengiz E, Özcengiz G (2013). Pertussis vaccines: state-
of-the-art and future trends. Curr Topics Medic Chem 13:
2581-2596.
- Warfel JM, Edwards KM (2015). Pertussis vaccines and the challenge
of inducing durable immunity.
Curr Opin Immunol 35: 48-54.
- WHO (2017). WHO Vaccine-Preventable Diseases: Monitoring
System. 2017 Global Summary. Geneva, Switzerland: WHO,
2017.
- Wu JR, Shien JH, Shieh HK, Chen CF, Chang PC (2007). Protective
immunity conferred by recombinant
Pasteurella
multocida
lipoprotein E (PlpE). Vaccine 25: 4140-4148.
- Xing D, Asokanathan C, Xu YH, Bolgiano B, Douglas-Bardsley
A, Zhang S, Wang J, Corbel M (2014). Relationship of
immunogenicity to protective potency in acellular pertussis
vaccines. Hum Vaccin Immunother 10:
2066-2073.
- Xu Y, Liu B, Gröndahl-Yli-Hannuksila K, Tan Y, Feng L, Kallonen T,
Wang L, Peng D, He Q, Wang L et al. (2015). Whole-genome
sequencing reveals the effect of vaccination on the evolution of
Bordetella
pertussis
. Sci Rep 5: 12888.
- Yılmaz Ç, Aycan A, Özcengiz E, Özcengiz G (2016). Immunogenicity
and protective efficacy of recombinant iron superoxide
dismutase protein from
Bordetella
pertussis
in mice models.
Microbiol Immunol 60:
717-724.